ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) and CorMedix (NYSE:CRMD – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

89.7% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 33.8% of CorMedix shares are held by institutional investors. 6.2% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ORIC Pharmaceuticals and CorMedix's net margins, return on equity and return on assets.

Volatility and Risk

Analyst Ratings

This is a breakdown of current ratings for ORIC Pharmaceuticals and CorMedix, as provided by MarketBeat.com.

ORIC Pharmaceuticals currently has a consensus price target of $22.00, suggesting a potential upside of 379.30%. Given ORIC Pharmaceuticals' higher probable upside, equities analysts clearly believe ORIC Pharmaceuticals is more favorable than CorMedix.

Earnings and Valuation

This table compares ORIC Pharmaceuticals and CorMedix's gross revenue, earnings per share and valuation.

CorMedix has higher revenue and earnings than ORIC Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

ORIC Pharmaceuticals beats CorMedix on 8 of the 12 factors compared between the two stocks.

About ORIC Pharmaceuticals

(Get Rating)

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About CorMedix

(Get Rating)

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.